Log in

SCPX Scorpius Holdings Inc. OTC · United States

Scorpius Holdings (SCPX) news

Scorpius Holdings Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SCPX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Scorpius Holdings news

We have not published a story on Scorpius Holdings yet. When there is news, it will appear here.

Questions about Scorpius Holdings

What is the ticker symbol of Scorpius Holdings?

Scorpius Holdings Inc. trades under the ticker SCPX on OTC.

Where is Scorpius Holdings listed?

Scorpius Holdings Inc. is listed on OTC.

Which country or territory is Scorpius Holdings listed under?

Our directory records Scorpius Holdings Inc. under United States.

What does Scorpius Holdings do?

Our directory classifies Scorpius Holdings Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Scorpius Holdings?

The ISIN recorded for Scorpius Holdings Inc. is US42237K5083.

Does aibio.space cover Scorpius Holdings?

aibio.space lists Scorpius Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Scorpius Holdings?

Companies in our directory listed in the same country and business area as Scorpius Holdings: Niki BioSolutions, Turn Therapeutics, Actuate Therapeutics, Context Therapeutics, Vertex Pharmaceuticals, Harmony Biosciences Holdings.

Investor discussion: Scorpius Holdings

Members talk about Scorpius Holdings (SCPX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:SCPX on TradingView.

Listing details

Scorpius Holdings Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SCPX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Scorpius Holdings Inc.
Ticker
SCPX
Listing
OTC
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US42237K5083
Last quote in directory
2026-10-19
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.